Neurogene Inc. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Neurogene Inc. (NGNE) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $64.01 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-12.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-03-12
- Neurogene Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was $16.48M.
- Neurogene Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was $31.48M.
- Neurogene Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was $16.16M.
- Neurogene Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-03-31 was -$108.00K, a 105.41% decline year-over-year.
- Neurogene Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was $64.01M.
- Neurogene Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$48.06M.
- Neurogene Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$47.53M.
- Neurogene Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$23.57M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 123 month |
|---|---|---|---|---|---|---|---|---|---|
| 2017-12-31 | $16.48M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $47.96M derived: sum of 2 quarters · filed 2018-03-12 | $64.12M derived: sum of 3 quarters · filed 2018-03-12 | $64.01M 10-K · filed 2018-03-12 | |||||
| 2017-09-30 | $31.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $47.63M derived: sum of 2 quarters · filed 2017-11-08 | $47.53M 10-Q · filed 2017-11-08 | $2.82M derived: sum of 4 quarters · filed 2018-03-12 | |||||
| 2017-06-30 | $16.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $16.05M 10-Q · filed 2017-08-08 | -$28.66M derived: sum of 3 quarters · filed 2018-03-12 | -$28.71M derived: sum of 4 quarters · filed 2018-03-12 | |||||
| 2017-03-31 | -$108.00K 10-Q · filed 2017-05-09 | -$44.81M derived: sum of 2 quarters · filed 2018-03-12 | -$44.86M derived: sum of 3 quarters · filed 2018-03-12 | -$50.16M derived: sum of 4 quarters · filed 2018-03-12 | |||||
| 2016-12-31 | -$44.70M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | -$44.76M derived: sum of 2 quarters · filed 2018-03-12 | -$50.05M derived: sum of 3 quarters · filed 2018-03-12 | -$48.06M 10-K · filed 2018-03-12 | |||||
| 2016-09-30 | -$52.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$5.35M derived: sum of 2 quarters · filed 2017-11-08 | -$3.35M 10-Q · filed 2017-11-08 | -$69.03M derived: sum of 4 quarters · filed 2018-03-12 | |||||
| 2016-06-30 | -$5.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | -$3.30M 10-Q · filed 2017-08-08 | -$68.98M derived: sum of 3 quarters · filed 2018-03-12 | -$62.92M derived: sum of 4 quarters · filed 2018-03-12 | |||||
| 2016-03-31 | $2.00M 10-Q · filed 2017-05-09 | -$63.68M derived: sum of 2 quarters · filed 2018-03-12 | -$57.63M derived: sum of 3 quarters · filed 2018-03-12 | -$51.60M derived: sum of 4 quarters · filed 2018-03-12 | |||||
| 2015-12-31 | -$65.68M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | -$59.62M derived: sum of 2 quarters · filed 2018-03-12 | -$53.59M derived: sum of 3 quarters · filed 2018-03-12 | -$47.53M 10-K · filed 2018-03-12 | |||||
| 2015-09-30 | $6.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $12.09M derived: sum of 2 quarters · filed 2016-11-09 | $18.15M 10-Q · filed 2016-11-09 | $24.20M derived: sum of 4 quarters · filed 2017-03-09 | |||||
| 2015-06-30 | $6.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $12.09M 10-Q · filed 2016-08-04 | $18.14M derived: sum of 3 quarters · filed 2017-03-09 | $20.34M derived: sum of 4 quarters · filed 2017-03-09 | |||||
| 2015-03-31 | $6.06M 10-Q · filed 2016-05-10 | $12.11M derived: sum of 2 quarters · filed 2017-03-09 | $14.32M derived: sum of 3 quarters · filed 2017-03-09 | -$17.51M derived: sum of 4 quarters · filed 2017-03-09 | |||||
| 2014-12-31 | $6.05M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09 | $8.26M derived: sum of 2 quarters · filed 2017-03-09 | -$23.57M derived: sum of 3 quarters · filed 2017-03-09 | -$23.57M 10-K · filed 2017-03-09 | -$23.57M 10-K · filed 2015-03-16 | ||||
| 2014-09-30 | $2.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-10 | -$29.62M derived: sum of 2 quarters · filed 2015-11-10 | -$29.62M 10-Q · filed 2015-11-10 | -$29.62M 10-Q · filed 2014-11-04 | -$32.44M derived: sum of 4 quarters · filed 2016-03-14 | ||||
| 2014-06-30 | -$31.83M 10-Q · filed 2014-08-11 | -$31.83M 10-Q · filed 2015-08-06 | -$31.83M 10-Q · filed 2014-08-11 | -$34.64M derived: sum of 3 quarters · filed 2016-03-14 | -$34.62M derived: sum of 4 quarters · filed 2016-03-14 | ||||
| 2014-03-31 | -$4.00K 10-Q · filed 2015-05-12 | -$4.46K 10-Q · filed 2014-05-13 | -$2.82M derived: sum of 2 quarters · filed 2016-03-14 | -$2.79M derived: sum of 3 quarters · filed 2016-03-14 | -$2.69M derived: sum of 4 quarters · filed 2016-03-14 | -$3.36M 10-Q · filed 2014-05-13 | |||
| 2013-12-31 | -$2.81M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | -$2.79M derived: sum of 2 quarters · filed 2016-03-14 | -$2.69M derived: sum of 3 quarters · filed 2016-03-14 | -$2.64M 10-K · filed 2016-03-14 | -$2.64M 10-K · filed 2015-03-16 | ||||
| 2013-09-30 | $26.45K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $128.27K derived: sum of 2 quarters · filed 2014-11-04 | $174.38K 10-Q · filed 2014-11-04 | ||||||
| 2013-06-30 | $101.82K 10-Q · filed 2014-08-11 | $147.93K 10-Q · filed 2014-08-11 | |||||||
| 2013-03-31 | $46.11K 10-Q · filed 2014-05-13 | ||||||||
| 2012-12-31 | -$6.45K 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |